Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: Comparison with selegiline

British Journal of Pharmacology

Volumn 143, Issue 3, 2004, Pages 371-378

  Abassi, Zaid A ^a   Binah, Ofer ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Deprenyl (selegiline); Dopamine; Irreversible inhibitors; Monoamine oxidase (MAO) A and B; Parkinson's disease; Rasagiline

Indexed keywords

AMINOINDAN; INDAN DERIVATIVE; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE B INHIBITOR; RASAGILINE; SELEGILINE; THIOBUTABARBITAL; TVP 136; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CAROTID ARTERY FLOW; CONTROLLED STUDY; DEPRESSOR RESPONSE; DOSE RESPONSE; HEART RATE; HYPOTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CARDIOVASCULAR PHYSIOLOGY; CAROTID ARTERIES; INDANS; INJECTIONS, INTRAVENOUS; METHAMPHETAMINE; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE; TIME FACTORS; VASCULAR RESISTANCE;

EID: 7044245505     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705962     Document Type: Article

References (38)

1. ABU-RAYA, S., TABAKMAN, R., BLAUGRUND, E., TREMBOVLER, V. & LAZAROVICI, P. (2002). Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur. J. Pharmacol., 434, 109-116.
2. AM, O.B., AMIT, T. & YOUDIM, M.B.H. (2004). Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett., 355, 169-172.
3. ANDREUCCI, V.E. (1978). Anesthesia for Micropuncture in rats. In: From Manual of Renal Micropuncture, ed. Vittorio E. Andreucci, p 43, Idelson Naoles: Naples, Italy.
4. BIRKMAYER, W., RIEDERER, P., AMBROZI, L. & YOUDIM, M.B.H. (1977). Implications of combined treatment with madopar and L-deprenyl in Parkinson disease. Lancet, 2, 439-443.
5. BIRKMAYER, W., RIEDERER, P., YOUDIM, M.B.H. & LINAUER, W. (1975). The potentiation of anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B deprenyl. J. Neural. Transm., 36, 303-326.
6. BROOKS, D.J. & SAGAR, H. (2003). U.K.-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomized, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry, 74, 1071-1079.
7. CHURCHYARD, A., MATHIAS, C.J., BOONKONGCHUEN, P. & LEES, A.J. (1997). Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 63, 228-234.
8. FINBERG, J.P., ARI, G., LAVIAN, G. & HOVEVEY-SION, D. (1990). Modification of alpha-2 presynaptic receptor activity and catecholamine release following chronic MAO inhibition. J Neural Transm. Suppl., 32, 405-412.
9. FINBERG, J.P.M., LAMENSDORF, I., WEINSTOCK, M., SCHWARTZ, M. & YOUDIM, M.B.H. (1999). Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv. Neurol., 80, 495-501.
10. FINBERG, J.P.M., SABBAGH, A. & YOUDIM, M.B.H. (1980). Pharmacology of selective propargyl suicide inhibitors of monoamine oxidase. In: Enzymes and Neurotransmitters in Mental Disease, eds. Usdin, E., Sourkes, T.L. & Youdim, M.B.H. pp. 207-219. Wiley: Chichester.
11. FINBERG, J.P. & YOUDIM, M.B.H. (2002). Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviors. Neuropharmacology, 43, 1110-1118.
12. FISCHER, J.E., WEISE, V.K. & KOPIN, I.J. (1968). False adrenergic transmitter release from the isolated cat heart. Am. J. Med. Sci., 255, 158-162.
13. GASSEN, M., LAMENSDORF, I., ARMONY, T., FINBERG, J.P. & YOUDIM, M.B.H. (2003). Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J. Neural. Transm., 110, 171-182.
14. GLEZER, S. & FINBERG, J.P. (2003). Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur. J. Pharmacol., 472, 173-177.
15. GOLDSTEIN, D.S., HOLMES, C, LI, S.T., BRUCE, S., METMAN. L.V. & CANNON III, R.O. (2000). Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med., 133, 338-347.
16. KALIR, A., SABBAGH, A. & YOUDIM, M.B.H. (1981). Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmacol., 73, 55-64.
17. KOPlN, I.J., WEISE, VK & SEDVALL, G.C. (1969). Effect of false transmitters on norepinephrine synthesis. J. Pharmacol. Exp. Ther., 170, 246-252.
18. KRAEMER, T. & MAURER, H.H. (2002). Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug. Monit., 24, 277-289.
19. LAVIAN, G., FINBERG, J.P. & YOUDIM, M.B.H. (1993). The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine. Clin. Neuropharmacol., 16 (Suppl. 2), S1-S7.
20. LEES, A., SHOW, K.M., KAHOUT, L.J., STERN, G., ELSWORTH, J.D., SANDLER, M. & YOUDIM, M.B.H. (1977). Deprenyl in Parkinson's disease. Lancet, 2, 791-795.
21. LEES, A.J. (1995). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson Disease Research Group of the United Kingdom. Br. Med. J., 311, 1601-1607.
22. MANDEL, S., GRUNBLATT, E., RIEDERER, P., GERLACH, M., LEVITES, Y. & YOUDIM, M.B.H. (2003). Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs., 17, 729-762.
23. MATHIAS, C.J. (1998). Cardiovascular autonomie dysfunction in Parkinsonian patients. Clin. Neurosci., 5, 153-166.
24. MECO, G., PRATESI, L. & BONIFATI, V. (1991). Cardiovascular reflexes and autonomic dysfunction in Parkinson's disease. J. Neural., 238, 195-199.
25. MONTASTRUC, J.L., CHAUMERLIAC, C., DESBOEUF, K., MANIKA, M., BAGHERI, H., RASCOL, O. & LAPEYRE-MESTRE, M. (2000). Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin. Neuropharmacol., 23, 271-275.
26. PARKINSON STUDY GROUP (DATATOP) (1989). Selegiline and Parkinson's disease. N. Engl. J. Med., 321, 1364-1371.
27. PARKINSON STUDY GROUP (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol., 59, 1937-1943.
28. PARKINSON STUDY GROUP (2004). A controlled randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol., 61, 561-566.
29. PAVESE, N., RIMOLDI, O., GERHARD, A., BROOKS, D.J. & PICCINI, P. (2004). Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov. Disord., 19, 298-303.
30. PAZOS, A., MEDIAVILLA, A. & FLOREZ, J. (1982). Cardiovascular effects of intracerebroventricular injection of dopamine after selective MAO inhibition in rats. Neuropharmacologv, 21, 317-322.
31. REYNOLDS, G.P., RIEDERER, P., SANDLER, N.R., JELLINGER, K. & SEEMALI, D. (1978). Amphetamine and 2-phenylethylamine in post mortem Parkinson brains after L-deprenyl administration. J. Neural. Transm., 43, 271-278.
32. RIEDERER, P. & RINNE, U.K. (1992). Selegiline in Parkinson's disease: An update. Mov. Disords., 8 (Suppl. 1), 51-54.
33. SHIN, H.S. (1997). Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug. Metab. Dispos., 25, 657-662.
34. SIMPSON, L.L. (1978). Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Bioehem. Pharmacol., 27, 1591-1595.
35. SZOKO, E., KALASZ, H. & MAGYAR, K. (1999). Biotransformation of deprenyl enantiomers. Eur. J. Drug. Metab. Pharmacokinet., 24, 315-319.
36. TURKKA, J.T., TOLONEN, U. & MYLLYLA, V.V. (1987). Cardiovascular reflexes in Parkinson's disease. Eur. Neurol., 26, 104-112.
37. YOUDlM, M.B.H. (2003). Rasagiline: an antiparkinson drug with neutroprotective activity. Expert. Rev. Neurotherapeut., 3, 737-749.
38. YOUDIM, M.B.H., GROSS, A. & FINBERG, J.P. (2001). Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br. J. Pharmacol., 132, 500-506.